Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4

ABSTRACT Chronic hepatitis B virus (HBV) infection can lead to liver cirrhosis and hepatocellular carcinoma. HBV reactivation during or after chemotherapy is a potentially fatal complication for cancer patients with chronic HBV infection. Transcription of HBV is a critical intermediate step of the HBV life cycle. However, factors controlling HBV transcription remain largely unknown. Here, we found that different P-TEFb complexes are involved in the transcription of the HBV viral genome. Both BRD4 and the super elongation complex (SEC) bind to the HBV genome. The treatment of bromodomain inhibitor JQ1 stimulates HBV transcription and increases the occupancy of BRD4 on the HBV genome, suggesting the bromodomain-independent recruitment of BRD4 to the HBV genome. JQ1 also leads to the increased binding of SEC to the HBV genome, and SEC is required for JQ1-induced HBV transcription. These findings reveal a novel mechanism by which the HBV genome hijacks the host P-TEFb-containing complexes to promote its own transcription. Our findings also point out an important clinical implication, that is, the potential risk of HBV reactivation during therapy with a BRD4 inhibitor, such as JQ1 or its analogues, which are a potential treatment for acute myeloid leukemia.

[1]  F. Zoulim,et al.  Current treatments for chronic hepatitis B virus infections. , 2016, Current opinion in virology.

[2]  Clifford A. Meyer,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[3]  C. Seeger,et al.  Molecular biology of hepatitis B virus infection. , 2015, Virology.

[4]  Marawan Ahmed,et al.  Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. , 2015, Drug discovery today.

[5]  Yuquan Wei,et al.  Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. , 2013, The international journal of biochemistry & cell biology.

[6]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[7]  P. Sebastiani,et al.  BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1 , 2012, Journal of leukocyte biology.

[8]  Gaurav D. Gaiha,et al.  Reactivation of latent HIV-1 by inhibition of BRD4. , 2012, Cell reports.

[9]  Qiang Zhou,et al.  The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation , 2012, Nucleic acids research.

[10]  B. Peterlin,et al.  Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein* , 2012, The Journal of Biological Chemistry.

[11]  A. Shilatifard,et al.  The super elongation complex (SEC) family in transcriptional control , 2012, Nature Reviews Molecular Cell Biology.

[12]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[13]  A. Shilatifard,et al.  The Super Elongation Complex Family of RNA Polymerase II Elongation Factors: Gene Target Specificity and Transcriptional Output , 2012, Molecular and Cellular Biology.

[14]  Fabien Zoulim,et al.  Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. , 2011, Journal of hepatology.

[15]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[16]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[17]  Madelaine Gogol,et al.  Dynamic transcriptional events in embryonic stem cells mediated by the super elongation complex (SEC). , 2011, Genes & development.

[18]  Ali Shilatifard,et al.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis , 2010, Nature Reviews Cancer.

[19]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[20]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[21]  P. Howley,et al.  Brd4-Independent Transcriptional Repression Function of the Papillomavirus E2 Proteins , 2007, Journal of Virology.

[22]  R. Mitra,et al.  Brd4 Is Required for E2-Mediated Transcriptional Activation but Not Genome Partitioning of All Papillomaviruses , 2006, Journal of Virology.

[23]  B. Peterlin,et al.  Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.

[24]  P. Howley,et al.  Bromodomain Protein 4 Mediates the Papillomavirus E2 Transcriptional Activation Function , 2006, Journal of Virology.

[25]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[26]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[27]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[28]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[29]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Manns,et al.  Structural organization of the hepatitis B virus minichromosome. , 2001, Journal of molecular biology.

[31]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.

[32]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[33]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Mullins,et al.  Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA , 1986, Cell.

[35]  H. Delius,et al.  Structure of the hepatitis B virus genome , 1983, Journal of virology.

[36]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[37]  T. Shikata,et al.  Two distinct types of hepatitis in experimental hepatitis B virus infection. , 1980, The American journal of pathology.

[38]  R. Greenman,et al.  DNA Polymerase Associated with Human Hepatitis B Antigen , 1973, Journal of virology.

[39]  Critical Reviews in Oncology/Hematology Hepatitis B and cancer: A practical guide for the oncologist , 2022 .